Amendments to the Claims:

15. (Currently Amended) A mammalian cell line comprising DNA encoding an interleukin-2 mutein having a mammalian glycosylation pattern, wherein the interleukin-2 mutein is numbered in accordance with wild-type interleukin-2 and the asparagine at position 88 of the wild-type interleukin-2 is substituted with arginine.

16. (Original) The mammalian cell line of claim 15 wherein the glycosylation is O-linked.

17. (Original) The mammalian cell line of claim 16 wherein the glycosylation comprises O-linked GalNAc, GalNAc-β-Gal, and GalNAc-β-Gal-α-NeuNAc.

18. (Original) The cell line of claim 15 wherein the cell line is a CHO cell line.

19. (Original) A plasmid comprising a DNA sequence encoding an interleukin-2 mutein having a mammalian glycosylation pattern, wherein the interleukin-2 mutein is numbered in accordance with wild-type interleukin-2 and the asparagine at position 88 of the wild-type interleukin-2 is substituted with arginine.

20. (Currently Amended) The plasmid of claim 19 as shown in the plasmid map of ~~the~~ Figure 1.

21. (Currently Amended) A method of producing an interleukin-2 mutein having a mammalian glycosylation pattern, wherein the interleukin-2 mutein is numbered in accordance with wild-type interleukin-2 and the asparagine at position 88 of the wild-type interleukin-2 is substituted with arginine, said method comprising the steps of:

a) obtaining a vector comprising a nucleic acid sequence coding for the interleukin-2 mutein, and

b) introducing the vector into a mammalian cell capable of expressing the interleukin-2 mutein.